Allarity Therapeutics Inc. has filed a prospectus supplement on April 15, 2024, to increase the maximum aggregate offering price of its common stock from $3,200,000 to $4,500,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $2,480,444 of its common stock within the last 12 months and is now eligible to sell an additional $2,024,359. The prospectus supplement is a continuation of the company's previous filings, including the prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The current public float market value of Allarity Therapeutics' common stock held by non-affiliates is approximately $13,514,408, with a per-share price of $8.56 as of February 28, 2024. The company is limited to selling no more than...Show More

Allarity Therapeutics Inc. has filed a prospectus supplement on April 15, 2024, to increase the maximum aggregate offering price of its common stock from $3,200,000 to $4,500,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $2,480,444 of its common stock within the last 12 months and is now eligible to sell an additional $2,024,359. The prospectus supplement is a continuation of the company's previous filings, including the prospectus dated November 29, 2023, and the prospectus supplement dated March 19, 2024. The current public float market value of Allarity Therapeutics' common stock held by non-affiliates is approximately $13,514,408, with a per-share price of $8.56 as of February 28, 2024. The company is limited to selling no more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $4,504,803, as long as the public float remains below $75 million. Investors are cautioned that investing in Allarity Therapeutics' common stock involves a high degree of risk, as detailed in the 'Risk Factors' section of the March 19, 2024, prospectus supplement.